Juno and Bristol-Myers Squibb suffer losses in Revlimid patent war
Intellectual Property 2021-03-25 1:58 pm | Sydney
A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.
For information on rights and reprints, contact subscriptions@lawyerly.com.au